Biogen topped fourth-quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment ...

Sanofi SAN-0.38%decrease; red down pointing triangle said a U.S. regulatory decision on its tolebrutinib experimental treatment for a type of multiple sclerosis would be delayed again, and that a late ...

On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...

Sanofi shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key goal and U.S. regulators signaling a decision on ...

An international research team has demonstrated that a new plant-derived drug can block the progression of multiple sclerosis (MS). University of Queensland researcher Dr Christian Gruber said the ...

Explore how Epstein-Barr may link to multiple sclerosis, affecting nearly one million people in the United States.

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...

Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced two Phase 3 trial successes for fenebrutinib, its new experimental drug ...

A federal judge in Illinois allowed a class action against Biogen Inc. to advance over the drugmaker’s alleged collusion with pharmacy benefit managers to favor its multiple sclerosis drug Tecfidera ...

An experimental drug originally identified in a National Cancer Institute library of chemical compounds as a potential therapy for brain and basal cell cancers improves the symptoms of mice with a ...